BCRX
BioCryst Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 12:48 UTC
Last close
7.63USD
Market data, 2026-11-05
Except where said otherwise: 10-K for 2025, filed 2026-02-26
6.1xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
30.2%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
39.4%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Safety is the furthest below its sector's middle: 0.49 against 0.53 on the market's range.
- Growth117.9%97 of 100, above its sector
- Returns on capital51.3%100 of 100, above its sector
- Margins97.8%96 of 100, above its sector
- Price6.1x71 of 100, above its sector
- Safety2.0649 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
5 of 5 readExcept where said otherwise: 10-K for 2025, filed 2026-02-26
- Sales3.93x
Its own average over 10 years, 222.4M.
- Profit-2.65x
Its own average over 10 years, -99.7M.
- Free cash flow-6.48x
Its own average over 10 years, -53.2M.
- Debt0.09x
Its own average over 10 years, 125.3M.
- Price0.98x
Its own average over 11 years, 8. Market data, 2026-11-05
Free cash flow is furthest from its own average, at -6.48 times.
Sales is 3.93 times its own 10-year average; Profit is -2.65 times its own 10-year average; Free cash flow is -6.48 times its own 10-year average; Debt is 0.09 times its own 10-year average; Price is 0.98 times its own 11-year average.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-26
Sales against its own 10-year average3.93
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Profit against its own 10-year average-2.65
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Free cash flow against its own 10-year average-6.48
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Debt against its own 10-year average0.09
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Price against its own 11-year average0.98Market data, 2026-11-05
- Source
- market
- Taken on
- 2026-11-05
- Reported in
- USD